Navigating the United States FDA advisory: Probiotics in Preterm Infants

Area of Science:

• Neonatal Medicine
• Gastroenterology
• Microbiology

Background:

• Necrotizing enterocolitis (NEC) is a critical gastrointestinal condition in preterm infants, associated with high mortality and long-term health issues.
• Probiotics have demonstrated significant efficacy in reducing NEC incidence, all-cause mortality, and late-onset sepsis in preterm infants through numerous studies.
• A recent FDA advisory has led to a sharp decline in probiotic use in US neonatal intensive care units, despite existing evidence and guidelines.

Purpose of the Study:

• To review the evidence supporting probiotic efficacy in preventing NEC.
• To examine the FDA's stated reasons for its advisory concerning probiotics.
• To contrast US policies with global practices and analyze the implications of reduced probiotic use.

Main Methods:

• Systematic review of randomized trials and meta-analyses on probiotic efficacy for NEC.
• Analysis of FDA advisory statements and safety concerns.
• Comparative assessment of US versus international clinical practices and guidelines.

Main Results:

• Multiple studies confirm probiotics significantly decrease severe NEC, mortality, and sepsis in preterm infants.
• FDA cited safety concerns, quality control issues, and unapproved drug status as reasons for its advisory.
• US probiotic use has decreased, diverging from international recommendations and potentially impacting infant outcomes.

Conclusions:

• Withholding probiotics may create a risk-benefit imbalance, denying preterm infants a potentially life-saving intervention.
• Regulatory reform, continued research, and collaboration are needed to address safety concerns and ensure access to probiotics.
• Revisiting US policy is crucial to align with global practices and safeguard vulnerable preterm populations.